Aflibercept, a fusion protein that binds VEGF-A, VEGF-B, and placental growth factor (PlGF), has shown potential in preclinical studies, although clinical trial data in IBD are still forthcoming [115]. Here, VEGFA is linked to inflammatory bowel disease.